Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2579180 | 0.83 | — | — | |
| SCHEMBL275279 | 0.83 | SMN1; SMN2 (0.48) | SMN1; SMN2CA14CA12KMT2AALDH1A1 | |
| SCHEMBL27310429 | 0.78 | ALDH1A1 (0.40) | KMT2AALDH1A1 | |
| SCHEMBL2727651 | 0.76 | SMN1; SMN2 (0.42) | SMN1; SMN2CA14CA12KMT2AALDH1A1 | |
| SCHEMBL9416774 | 0.76 | — | — | |
| SCHEMBL276322 | 0.76 | KMT2A (0.43) | SMN1; SMN2CA14CA12KMT2AALDH1A1 | |
| SCHEMBL5840367 | 0.74 | SMN1; SMN2 (0.40) | SMN1; SMN2CA14CA12KMT2AALDH1A1 | |
| SCHEMBL11145342 | 0.72 | SMN1; SMN2 (0.43) | SMN1; SMN2CA14CA12KMT2AALDH1A1 | |
| SCHEMBL9867193 | 0.72 | SMN1; SMN2 (0.39) | SMN1; SMN2CA14CA12KMT2AALDH1A1 | |
| SCHEMBL9867191 | 0.72 | SMN1; SMN2 (0.39) | SMN1; SMN2CA14CA12KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989625-B2 | Thienopyridines | MERCK PATENT GMBH (DE) | 2011-08-02 | — | — | US | disclosed |
| US-20100048558-A1 | THIENOPYRIDINES | MERCK PATENT GESELLSCHAFT (DE) | 2010-02-25 | — | — | US | disclosed |
| US-20030138432-A1 | Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs | DRUG INNOVATION & DESIGN, INC. | 2003-07-24 | — | — | US | disclosed |
| EP-1255567-A1 | SELECTIVE CELLULAR TARGETING: MULTIFUNCTIONAL DELIVERY VEHICLES | Drug Innovation & Design, Inc. (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001036003-A2 | SELECTIVE CELLULAR TARGETING: MULTIFUNCTIONAL DELIVERY VEHICLES | DRUG INNOVATION & DESIGN, INC. (US) | 2001-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048558-A1 | THIENOPYRIDINES | HSP90AB2P, HSP90AB1, HSP90AA1 | SMN1; SMN2 3773/4885CA14 4883/4885CA12 4879/4885 |
| US-20030138432-A1 | Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs | PAICS, ABCB1, ABCG2 | SMN1; SMN2 2681/4885CA14 1644/4885CA12 1525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.